Data completeness
2/8 — Basic
FUROSEMIDE (furosemide) by R-Pharm US is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals.
Drug data last refreshed 13h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle, making it highly efficacious for fluid removal. It is indicated for edema and hypertension management across multiple patient populations. The drug has a rapid onset (5 minutes IV, later IM/oral) with peak effect within 30 minutes and a ~2 hour duration of action.
PRE_LAUNCH
Pre-launch status suggests small team building phase; career opportunity lies in launch planning and market entry strategy development.
Mechanism of Action
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption…
Worked on FUROSEMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.